Inovio Pharmaceuticals {NASDAQ: INO} announced today that pre-clinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential to prevent and treat infections from this harmful pathogen.
Inovio expects to test their Zika vaccine on humans in 2016.
Continue reading








